Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HRS-5346
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : $1,970.0 million
Deal Type : Licensing Agreement
Merck Licenses HRS-5346, Oral Lipoprotein(a) Inhibitor, from Jiangsu Hengrui
Details : Under the licensing agreement, Merck will hold the rights of HRS-5346, an investigational oral small molecule Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China.
Product Name : HRS-5346
Product Type : Other Small Molecule
Upfront Cash : $200.0 million
March 25, 2025
Lead Product(s) : HRS-5346
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : $1,970.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Elevar Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Rejects Hengrui, Elevar's PD-1 Cancer Drug Combo—Again
Details : SHR-1210 (camrelizumab) in combination with rivoceranib (apatinib) is being evluated for the treatment of first-line therapy in patients With advanced hepatocellular carcinoma.
Product Name : SHR-1210
Product Type : Antibody
Upfront Cash : Inapplicable
March 21, 2025
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Elevar Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
IDEAYA, Hengrui License Phase 1 DLL3 ADC SHR-4849 Targeting SCLC And NET Tumors
Details : Under the licensing agreement, IDEAYA will develop and commercialize SHR-4849 for solid tumors, including SCLC and NET, globally, excluding Greater China.
Product Name : SHR-4849
Product Type : Other Large Molecule
Upfront Cash : $75.0 million
December 29, 2024
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Mycovia Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Mycovia Announces VIVJOA® Launch for Severe Vulvovaginal Candidiasis in China
Details : Vivjoa (oteseconazole) is a selective and orally bioavailable CYP51 inhibitor antifungal, which is approved in China for the treatment of severe vulvovaginal candidiasis.
Product Name : Vivjoa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2024
Lead Product(s) : Oteseconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Mycovia Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Under the agreement, Merck will develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167 and Claudin-18.2 antibody-drug conjugate (ADC) SHR-A1904.
Product Name : HRS-1167
Product Type : Other Small Molecule
Upfront Cash : $169.3 million
October 30, 2023
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Camrelizumab (SHR-1210) is a humanized monoclonal antibody targeting the programmed death-1 (PD-1) receptor. Blockade of the PD-1/PD-L1 signaling pathway is a therapeutic strategy showing success in a wide variety of solid and hematological cancers.
Product Name : SHR-1210
Product Type : Antibody
Upfront Cash : Inapplicable
October 09, 2022
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
